{"Clinical Trial ID": "NCT00537771", "Intervention": ["INTERVENTION 1:", "- Arimidex Group", "Anastrozole (ARMIDEX): 1 mg once daily", "INTERVENTION 2:", "- TAM Group", "Tamoxifene: 20 mg once daily"], "Eligibility": ["Incorporation criteria:", "Invasive breast cancer HR+ has been shown to be histologically", "All primary surgery and chemotherapy (if any) were completed and were likely to receive adjuvant hormonal therapy.", "Menopausal women", "- Exclusion criteria:", "Clinical evidence of metastatic disease", "Previous adjuvant hormone treatment for breast cancer", "Liver diseases"], "Results": ["Performance measures:", "Incidence of foie gras disease", "The main objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant therapy in terms of incidence of foie gras diseases.", "Duration: 48 weeks, 96 weeks, 144 weeks", "Results 1:", "Title of the arm/group: Arimidex Group", "Description of the arm/group: Anastrozole(ARIMIDEX): 1 mg once daily", "Total number of participants analysed: 178", "Type of measurement: Number", "Unit of measure: participants 48 weeks: 9", "96 weeks: 15", "144 weeks: 26", "Results 2:", "Title of the arm/group: TAM Group", "Description of the arm/group: Tamoxifene: 20 mg once daily", "Total number of participants analysed: 175", "Type of measurement: Number", "Unit of measure: participants 48 weeks: 53", "96 weeks: 66", "144 weeks: 72"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/178 (2.25 per cent)", "1/178 (0.56%)", "Superventricular extrasystoles 0/178 (0.00 %)", "Hepatic cyst 1/178 (0.56%)", "Cervicitis 0/178 (0.00 %)", "Autumn 1/178 (0.56%)", "1/178 (0.56%)", "1/178 (0.56%)", "- Cyst 0/178 (0.00 per cent)", "uterine antonia 0/178 (0.00 %)", "Adverse Events 2:", "Total: 4/175 (2.29 per cent)", "- Heart failure 0/175 (0.00 %)", "1/175 (0.57%)", "Hepatic cyst 0/175 (0.00 %)", "Cervicitis 2/175 (1.14 per cent)", "Autumn 0/175 (0.00 %)", "Dislocation of joints 0/175 (0.00 %)", "- Spinal fracture 0/175 (0.00 %)", "- Cyst 1/175 (0.57%)", "1/175 (0.57%)"]}